Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

Year in Review 2024 - NSCLC Perioperative Therapy

Oncology 2024 Year in Review

B. Halmos

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

The Non-Invasive Diagnosis of Lung Cancer

Memorial Sloan Kettering Cancer Center

G. Rocco

Nodules and Lung Cancer Screening

Fox Chase Cancer Center

R. Kumar

Role of Surgery in Locally Advanced NSCLC

Memorial Sloan Kettering Cancer Center

K. Gray

Neoadjuvant vs. Adjuvant: A New Paradigm for NSCLC

Total Health

D. Carbone

ESMO 2024 Summary: Key Trial Insights on Managing NSCLC With Low PD-…

ecancer

L. Paz-Ares

Thoracic Malignancies From an Interventional Pulmonologist's Perspec…

Fox Chase Cancer Center

C. Manley

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

Rad Onc 101: Radiation Oncology Basics

Nina Niu Sanford

N. Sanford

Adjuvant & Neoadjuvant Therapy in Early NSCLC With Actionable Genomi…

Fox Chase Cancer Center

J. Reuss

IO Advances in Metastatic NSCLC Treatment

Fox Chase Cancer Center

H. Borghaei

EGFRm Lung Cancer: Overview & Treatment Sequence

GRACE

J. Rotow

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

FDA Approval of Zenocutuzumab for Advanced NRG1 Fusion-Positive NSCL…

Memorial Sloan Kettering Cancer Center

A. Schram

Surveillance Imaging in Solid Tumors: More Complicated Than It Appea…

ecancer

C. Booth

Unresectable Stage 3 NSCLC: Patient Selection and Treatment Options

Fox Chase Cancer Center

C. Aggarwal